Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018

 

  • EMA’s human medicines committee (CHMP) recommended four medicines for approval, including a medicine for use in countries outside the European Union, at its November 2018 meeting.

 

London, UK (November 16, 2018) – The CHMP adopted a positive opinion for Fexinidazole Winthrop (fexinidazole), the first oral-only medicine (tablets) for the treatment of human African trypanosomiasis, commonly known as sleeping sickness, due to Trypanosoma brucei gambiense. This is the tenth medicine recommended by EMA under Article 58, a mechanism that allows the CHMP to assess and give opinions on medicines for use outside the European Union. For more information, please see the press release in the grid below.

Erleada (apalutamide) received a positive opinion for the treatment of non-metastatic castration resistant prostate cancer.

The CHMP recommended granting a marketing authorisation for Macimorelin Aeterna Zentaris (macimorelin), for the diagnosis of growth hormone deficiency in adults.

The generic medicine Silodosin Recordati (silodosin) received a positive opinion from the CHMP for the treatment of the signs and symptoms of benign prostatic hyperplasia.


Four recommendations on extensions of therapeutic indication

The Committee recommended extensions of indication for Kisqali, Mabthera, Orkambi and Ravicti.


Positive recommendations on extension of therapeutic indication following re-examination

The Committee recommended an extension of therapeutic indication for Blincyto (blinatumomab) in patients with residual cancer cells in the body after previous treatment, after re-examining its negative opinion for this medicine adopted in July 2018.

The CHMP also adopted a positive opinion for the use of Opdivo (nivolumab) and Yervoy (ipilimumab) in combination to treat renal cell carcinoma (kidney cancer), after re-examining its negative opinion adopted in July 2018.

For more information on these positive opinions following re-examination please see the question-and-answer documents in the grid below.


Outcome of review on quinolone and fluoroquinolone antibiotics

The CHMP recommended suspending some quinolone and fluoroquinolone antibiotics and introducing changes including restrictions on the use of all others following a review of disabling and potentially permanent side effects reported with these medicines. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on these medicines in June 2018. For more information, please see the public health recommendation in the grid below.


Withdrawal of extension of indication application

The application to extend the use of Tecentriq (atezolizumab) to treat kidney cancer was withdrawn. A question-and-answer document on this withdrawal is available in the grid below.


Agenda and minutes

The agenda of the November 2018 meeting is published on EMA’s website. Minutes of the October 2018 CHMP meeting will be published in the coming weeks.


CHMP
statistics

Key figures from the November 2018 CHMP meeting are represented in the graphic below.

 

CHMP n


Positive recommendations on new medicines

 

Name of medicine Erleada
INN apalutamide
Marketing-authorisation applicant Janssen-Cilag International N.V.
Therapeutic indication Treatment of non-metastatic castration resistant prostate cancer

 

Name of medicine Macimorelin Aeterna Zentaris
INN macimorelin
Marketing-authorisation applicant Aeterna Zentaris GmbH
Therapeutic indication Diagnosis of growth hormone deficiency in adults

List item

CHMP summary of positive opinion for Macimorelin Aeterna Zentaris (PDF/62.48 KB)

Adopted

First published: 16/11/2018
EMA/CHMP/777751/2018

 

Positive recommendation on new generic medicine

 

Name of medicine Silodosin Recordati
INN silodosin
Marketing-authorisation applicant Recordati Ireland Ltd
Therapeutic indication Treatment of the signs and symptoms of benign prostatic hyperplasia

List item

CHMP summary of positive opinion for Silodosin Recordati (PDF/73.33 KB)

Adopted

First published: 16/11/2018
EMA/766073/2018

 

Positive recommendation on medicine for use outside the European Union

 

Name of medicine Fexinidazole Winthrop
INN fexinidazole
Opinion holder sanofi-aventis groupe
Therapeutic indication Treatment of human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense
More information Press release: CHMP recommends first oral-only treatment for sleeping sickness

List item

CHMP summary of opinion for Fexinidazole Winthrop (PDF/73.53 KB)

Adopted

First published: 16/11/2018
EMA/791484/2018

 

Positive recommendations on extensions of indications

 

Name of medicine Kisqali
INN ribociclib
Marketing-authorisation applicant Novartis Europharm Limited

List item

CHMP post-authorisation summary of positive opinion for Kisqali (II-04) (PDF/64.74 KB)

Adopted

First published: 16/11/2018
EMA/CHMP/795769/2018

Name of medicine Mabthera
INN rituximab
Marketing-authorisation applicant Roche Registration GmbH

List item

CHMP post-authorisation summary of positive opinion for MabThera (II-149) (PDF/71.67 KB)

Adopted

First published: 16/11/2018
EMA/CHMP/790642/2018

Name of medicine Orkambi
INN lumacaftor / ivacaftor
Marketing-authorisation applicant Vertex Pharmaceuticals (Europe) Ltd

List item

CHMP post-authorisation summary of positive opinion for Orkambi (X-34-G) (PDF/67.93 KB)

Adopted

First published: 16/11/2018
EMA/774653/2018

Name of medicine Ravicti
INN glycerol phenylbutyrate
Marketing-authorisation applicant Horizon Pharma Ireland Limited

 

Positive recommendations on extensions of indications following re-examination

 

Name of medicine Blincyto
INN blinatumomab
Marketing-authorisation applicant Amgen Europe B.V.

List item

CHMP post-authorisation summary of positive opinion for Blincyto (II-0011) (PDF/69.16 KB)

Adopted

First published: 16/11/2018
EMA/CHMP/799482/2018

List item

Questions and answers on the positive opinion on the change to the marketing authorisation for Blincyto (blinatumomab) (PDF/76.47 KB)

Adopted

First published: 16/11/2018
EMA/800602/2018

Name of medicine Opdivo
INN nivolumab
Marketing-authorisation applicant Bristol-Myers Squibb Pharma EEIG

List item

CHMP post-authorisation summary of positive opinion for Opdivo (WS-1278) (PDF/72.85 KB)

Adopted

First published: 16/11/2018
EMA/CHMP/788598/2018

Name of medicine Yervoy
INN ipilimumab
Marketing-authorisation applicant Bristol-Myers Squibb Pharma EEIG

List item

CHMP post-authorisation summary of positive opinion for Yervoy (WS-1278) (PDF/71.11 KB)

Adopted

First published: 16/11/2018
EMA/795695/2018

 

Public-health recommendation

 

Name of medicine Quinolone- and fluoroquinolone-containing medicinal products
INN nalidixic acid, pipemidic acid, cinoxacin, enoxacin, pefloxacin, lomefloxacin, ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, norfloxacin, prulifloxacin, rufloxacin, flumequin

List item

Quinolone and fluoroquinolone Article-31 referral – Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics (PDF/81.98 KB)


First published: 16/11/2018
EMA/795349/2018

 

Outcomes of arbitration procedures

 

Name of medicine Diclofenac sodium spray gel 4%
INN diclofenac

List item

Diclofenac Article 29(4) referral – EMA recommends authorisation of Diclofenac Sodium Spray Gel 4% (diclofenac) in the EU (PDF/77.59 KB)


First published: 16/11/2018
EMA/631720/2018

Name of medicine Diotop capsules
INN diclofenac / omeprazole

List item

Diotop Article 29(4) referral – EMA recommends authorisation of Diotop (diclofenac / omeprazole capsules) in the EU (PDF/76.5 KB)


First published: 16/11/2018
EMA/790726/2018


Withdrawal of extension of indication application

 

Name of medicine Tecentriq
INN atezolizumab
Marketing-authorisation applicant Roche Registration GmbH

List item

Questions and answers on the withdrawal of application for a change to the marketing authorisation for Tecentriq (atezolizumab) (PDF/112.51 KB)


First published: 16/11/2018
EMA/798527/2018

 

Other updates

 

List item

Start of community reviews – CHMP meeting of 12-15 November 2018 (PDF/66.92 KB)


First published: 16/11/2018
EMA/712987/2018

List item

Scientific advice and protocol assistance adopted during the CHMP meeting 12-15 November 2018 (PDF/123.54 KB)

Adopted

First published: 16/11/2018
EMA/CHMP/SAWP/800757/2018

 

Related content

 

Blincyto: EPAR

Kisqali: EPAR

MabThera: EPAR

Opdivo: EPAR

Orkambi: EPAR

Ravicti: EPAR

Tecentriq: EPAR

Yervoy: EPAR

Opdivo: Pending EC decision

Kisqali: Pending EC decision

Opdivo: Withdrawn application

Macimorelin Aeterna Zentaris: Pending EC decision

MabThera: Pending EC decision

Orkambi: Pending EC decision

Tecentriq: Withdrawn application

Opdivo: Withdrawn application

Yervoy: Pending EC decision

Blincyto: Pending EC decision

Silodosin Recordati: Pending EC decision

Opdivo: Withdrawn application

Erleada: Pending EC decision

Yervoy: Paediatric investigation plan

Yervoy: Paediatric investigation plan

MabThera: Paediatric investigation plan

MabThera: Paediatric investigation plan

Blincyto: Paediatric investigation plan

Opdivo: Paediatric investigation plan

Opdivo: Paediatric investigation plan

Orkambi: Paediatric investigation plan

Blincyto: Orphan designation

Ravicti: Orphan designation

Ravicti: Orphan designation

Ravicti: Orphan designation

Ravicti: Orphan designation

Ravicti: Orphan designation

Ravicti: Orphan designation

Diclofenac Sodium Spray Gel 4%: Article 29(4) referrals

Diotop capsules: Article 29(4) referrals

Quinolone- and fluoroquinolone-containing medicinal products: Article 31 referrals

 

Medicines for use outside the EU

 

Fexinidazole Winthrop H-W-2320

 

Related content

CHMP recommends first oral-only treatment for sleeping sickness

Committee for Medicinal Products for Human Use (CHMP): 12-15 November 2018

CHMP: Agendas, minutes and highlights

Please note that not all documents associated with this page are published at the same time. This page is updated with new documents as soon as they become available. Therefore, users are asked to check the page regularly.


European Medicines Agency, 16.11.2018 (tB).

Schlagwörter: , ,

MEDICAL NEWS

New guidance to prevent the tragedy of unrecognized esophageal intubation
Overly restrictive salt intake may worsen outcomes for common form…
COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Scientists discover how salt in tumours could help diagnose and…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Kaltplasma bei diabetischem Fußsyndrom wirkt via Wachstumsfaktoren
Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…

ERNÄHRUNG

Gesunde Ernährung: „Nicht das Salz und nicht das Fett verteufeln“
Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?

ONKOLOGIE

Nahrungsergänzungsmittel während der Krebstherapie: Es braucht mehr Bewusstsein für mögliche…
Fusobakterien und Krebs
Fortgeschrittenes Zervixkarzinom: Pembrolizumab verlängert Leben
Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
Aktuelle Kongressdaten zum metastasierten Mammakarzinom und kolorektalen Karzinom sowie Neues…

MULTIPLE SKLEROSE

Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…